Quinazoline derivatives as kinase inhibitors

A compound selected from the group consisting of:

• {4-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}-N-(4-naphthyloxyphenyl)carboxamide
• {4-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}-N-(4-phenoxyphenyl)carboxamide
• {4-[6-methoxy-7-(ethoxy)quinazolin-4-yl]piperazinyl}-N-(4-phenoxyphenyl)carboxamide
• {4-[6-methoxy-7-(ethoxy)quinazolin-4-yl]piperazinyl}-N-(4-phenyecarboxamide
• {4-[6-methoxy-7-(ethoxy)quinazolin-4-yl]piperazinyl}-N-(4-cyanophenyl)carboxamide
• {4-[6-methoxy-7-(prop-2-enylethoxy)quinazolin-4-yl]piperazinyl}-N-(4-cyanophenyl)carboxamide
• {4-[6-methoxy-7-(prop-2-enylethoxy)quinazolin-4-yl]piperazinyl}-N-(4-methylethoxyphenyl)carboxamide
• [4-(6-methoxy-7-prop-2-enyloxyquinazolin-4-yl)piperazinyl]-N-(4-naphthyloxyphenyl)carboxamide
• N-(4-indol-4-yloxyphenyl)[4-(6-methoxy-7-prop-2-enyloxyquinazolin-4-yl)piperazinyl]carboxamide
• [4-(6-methoxy-7-prop-2-enyloxyquinazolin-4-yl)piperazinyl]-N-(4-phenoxyphenyl)carboxamide
• N-(4-cyanophenyl)[4-(6-methoxy-7-prop-2-ynyloxyquinazolin-4-yl)piperazinyl]carboxamide
• [4-(6-methoxy-7-prop-2-ynyloxyquinazolin-4-yl)piperazinyl]-N-(4-(methylethoxy)phenyl]carboxamide
• [4-(6-methoxy-7-prop-2-ynyloxyquinazolin-4-yl)piperazinyl]-N-(4-naphthyloxyphenyl)carboxamide
• N-(4-indol -4-yloxyphenyl)[4-(6-methoxy-7-prop-2-ynyloxy quinazolin-4-yl)piperazinyl]carboxamide
• [4-(6-methoxy-7-prop-2-ynyloxyquinazolin-4-yl)piperazinyl]-N-(4-phenoxyphenyl)carboxamide
• {4-[7-(2-hydroxy-3-piperidylpropoxy)-6-methoxyquinazolin-4-yl]piperazinyl}-N-[4-(methylethoxy)phenyl]carboxamide
• {4-[7-(2-fluoro-3-piperidylpropoxy)-6-methoxyquinazolin-4-yl]piperazinyl}-N-[4-(methylethoxy)phenyl]carboxamide
• [4-(6-methoxy-7-{3-[(2-methylpropyl)sulfonyl]propoxy}quinazolin-4-yl)piperazinyl]-N-[4-(methylethoxy)phenyl]carboxamide
• (4-{6-methoxly-7-[3-(propylsulfonyl)propoxy]quinazolin-4-yl}piperazinyl)-N-[4-(methylethoxy)phenyl]carboxamide
• methyl 4-({4-[6-methoxy-7-(3-pyrrolidinylpropoxy) quinazolin-4-yl]piperazinyl}carbonylamino)benzoate
• N-(4-acetylphenyl){4-[6-methoxy-7-(3-pyrrolidinylpropoxy) quinazolin-4-yl]piperazinyl}carboxamide
• N-(4-bromophenyl){4-[6-methoxy-7-(3-pyrrolidinylpropoxy) quinazolin-4-yl]piperazinyl}carboxamide
• {4-[6-methoxy-7-(3-pyrrolidinylpropoxy)quinazolin-4-yl]piperazinyl}-N-[4-(trifluoromethyl)phenyl]carboxamide
• {4-[6-methoxy-7-(3-pyrrolidinylpropoxy)quinazolin-4-yl]piperazinyl}-N-(4-methylphenyl)carboxamide
• {4-[6-methoxy-7-(3-pyrrolidinylpropoxy)quinazolin-4-yl]piperazinyl}-N-[4-(methylsulfonyl)phenyl]carboxamide
• N-(4-fluorophenyl){4-[6-methoxy-7-(3-pyrrolidinylpropoxy) quinazolin-4-yl]piperazinyl}carboxamide
• 4-({4-[6-methoxy-7-(3-pyrrolidinylpropoxy) quinazolin-4-yl]piperazinyl}carbonylamino)benzoic acid
• and all pharmaceutically acceptable salts or hydrates thereof.

A method of inhibiting phosphorylation of PDGF receptor in a patient comprising the step of administering a compound of the formula:

• wherein
• R1 is a member selected from the group consisting of:
• CN, —X, —CX3, —R5, —CO2R5, —C(O)R5, —SO2R5, —O—C1-8alkyl that is straight or branched chained, —O-phenyl, —O-naphthyl, —O-indolyl and —O-isoquinolinyl X is halogen;
• R5 is hydrogen or a C1-8alkyl that is straight or branched chained;
• R2 is —O-CH3;
• R4 is a member selected from the group consisting of:
• —O—CH2—CH═CH2, —O—CH2—C═CH, —O(CH2)n—SO2—R5 and —O—CH2—CH(R6)CH2—R3;
• R6 is —OH, —X, or a C1-8alkyl that is straight or branched chained;
• n is 2 or 3;
• R3 is a member selected from the group consisting of:
• —OH, —O-CH3, —O-CH2—CH3, —NH2, —N(—CH3)2, —NH(—CH2-phenyl), —NH(-phenyl), —CN
• and all pharmaceutically acceptable salts and hydrates thereof to the patient.

A method for inhibiting abnormal cell growth and cell wandering in a patient and thereby preventing or treating a cell-proliferative disease, comprising the step of administering a compound of the formula:

• wherein
• R1 is a member selected from the group consisting of:
• CN, —X, —X3, —R5, —CO2R5, —C(O)R5, —SO2R5, —O—C1-8 alkyl that is straight or branched chained, —O-phenyl, —O-naphthyl, —O-indolyl and —O-isoquinolinyl X is halogen;
• R5 is hydrogen or a C1-8alkyl that is straight or branched chained;
• R2 is —O—CH3;
• R4 is a member selected from the group consisting of :
• —O—CH2—CH═CH2, —O—CH2—C═CH, —O(CH2)n—SO2—R5 and —O—CH2—CH(R6)CH2—R3;
• R6 is —OH, —X, or a C1-8alkyl that is straight or branched chained;
• n is 2 or 3;
• R3 is a member selected from the group consisting of:
• —OH, —O-CH3, —O—CH2—CH3, —NH2, —N(—CH3)2, —NH(—CH2-phenyl), —NH(-phenyl), —CN
• and all pharmaceutically acceptable salts and hydrates thereof to the patient.

The method for treating cancer in a patient, comprising the step of administering a compound having the formula I(g) or formula I(h) as follows:

• wherein
• R1 is a member selected from the group consisting of:
• CN, —O-methyl, —O-ethyl, —O-propyl, —O-isopropyl, —O-butyl, —O-t-butyl, —O-isoamyl, 1-naphthyloxy, 2-naphthyloxy, 4-indolyloxy, 5-indolyloxy, 5-isoquinolyloxy;
• n is 2 or 3;
• R3 is a member selected from the group consisting of:
• —OH, —O—CH3, —O—CH2—CH3, —NH2, —N(—CH3)2, —NH(—CH2-phenyl), —NH(—phenyl), —CN
• and all pharmaceutically acceptable salts and hydrates thereof.